Pharmaceutical Benefits Scheme Drug Listings

Follow the links below to find information about the listing of drugs on the Pharmaceutical Benefits Scheme (PBS).

 

Updated January 2008

Printer friendly page

21 Resources Found
Results 1 to 20 displayed.
1    2   
Title:   Subsidised medicines for Aboriginal and Torres Strait Islander people
Publisher:   Australian Prescriber
Description:   Since August 2006, the Pharmaceutical Benefits Scheme (PBS) has been including new listings specifically for the treatment of common conditions in Aboriginal and Torres Strait Islander people.
Date:   Aug 2008
Title:   PBS
Publisher:   Australian Government Department of Health and Ageing
Description:   This web site contains the Schedule of Pharmaceutical Benefits, a listing of the medicines subsidised by the Australian Government.
Date:   May 2008
Title:   Media release. New PBS listings for May 2008
Publisher:   Australian Government Department of Health and Ageing
Description:   Women with advanced breast cancer, people with hypertension and people with osteoporosis will benefit from new listings on the Pharmaceutical Benefits Scheme.
Date:   May 2008
Title:   New quit smoking drug varenicline (Champix ®) added to PBS
Publisher:  
Description:   Varenicline has been listed under the PBS (Pharmaceutical Benefits Scheme) from January 1 2008.
Date:   Jan 2008
Title:   New listings for the treatment of age-related macular degeneration
Publisher:   Australian Government Department of Health and Ageing
Description:   LUCENTIS? (ranibizumab) is a new drug that will be listed on the Pharmaceutical Benefits Scheme from 1 August 2007 for the treatment of wet age related macular degeneration.
Date:   Jun 2007
Title:   Media release. New ADHD drug subsidised
Publisher:   Australian Government Department of Health and Ageing
Description:   A new drug for the treatment of attention deficit hyperactivity disorder will be listed from 1 July 2007 on the Pharmaceutical Benefits Scheme. The drug, Strattera? (atomoxetine), will provide treatment for children between the ages of six and 18 years who cannot take stimulants.
Date:   Apr 2007
Title:   PBAC: taxanes
Publisher:   Australian Prescriber
Description:   The listing of trastuzumab on the Pharmaceutical Benefits Scheme (PBS) in October 2006 was heralded with much fanfare. Along with this listing, changes to the prescribing requirements for taxanes also occurred.
Date:   Feb 2007
Title:   Listing of Herceptin on the PBS
Publisher:   Australian Government Department of Health and Ageing
Description:   The Government has accepted a recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) to list the drug trastuzumab (Herceptin?) on the Pharmaceutical Benefits Scheme (PBS).
Date:   Oct 2006
Title:   Insulin drugs to be listed on Pharmaceutical Benefits Scheme
Publisher:  
Description:   Lantus? (insulin glargine) and Levemir? (insulin detemir), will be available on the Pharmaceutical Benefits Schem (PBS) from 1 October 2006 for the treatment of patients with diabetes.
Date:   Aug 2006
Title:   Herceptin to be listed on the Pharmaceutical Benefits Scheme
Publisher:  
Description:   The Australian Government has announced that the cancer drug, Herceptin? (trastuzumab), will be listed on the Pharmaceutical Benefits Scheme (PBS) from 1 October 2006 for the treatment of patients with HER2 positive early stage breast cancer following surgery.
Date:   Aug 2006
Title:   Profile of a consumer representative - listing and pricing PBS medicines
Publisher:   Consumers' Health Forum of Australia (CHF)
Description:   A consumer representative discusses his work on the Pharmaceutical Benefits Advisory Committee which advises the Minister about which drugs should be listed on the PBS.
Date:   Jan 2006
Title:   Working together to improve the Pharmaceutical Benefits Scheme - Review of post PBAC processes report
Publisher:   Australian Government Department of Health and Ageing
Description:   The Review of post Pharmaceutical Benefits Advisory Committee (PBAC) processes has been a collaborative effort between the Department and Medicines Australia to explore innovative options to reduce the time taken to list approved drugs on the Pharmaceutical Benefits Scheme (PBS) so that they are more quickly available to the Australian community.
Date:   Aug 2005
Title:   Information about price changes in the 1 August Schedule of Pharmaceutical Benefits
Publisher:   Australian Government Department of Health and Ageing
Description:   Information for doctors, pharmacists and consumers about price changes in the 1 August 2005 issue of the Schedule of Pharmaceutical Benefits. Some of the price changes in the Schedule are a result of the Government's 12.5% price reduction policy. Under this new policy, when a manufacturer seeks to list the first new generic brand of a medicine already included on the PBS, it will need to offer a minimum 12.5% price reduction in the Government price for the medicine.
Date:   Aug 2005
Title:   Risperidone (Risperdal) for behavioural disturbances in dementia
Publisher:   Australian Prescriber
Description:   Risperidone has been PBS-listed as an authority item for behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful.
Date:   Jun 2005
Title:   Oral isotretinoin
Publisher:   Australian Prescriber
Description:   Oral isotretinoin is listed on the Australian Pharmaceutical Benefits Scheme for patients with severe cystic acne that has failed to respond adequately to other therapy. A single course of isotretinoin induces a long-term remission in over 80% of these patients.
Date:   Jun 2005
Title:   Response to the proposed new pricing and listing arrangements for generic medicines on the Pharmaceutical Benefits Scheme (2004 Election Commitment)
Publisher:   Consumers' Health Forum of Australia (CHF)
Description:   Health consumers value the PBS but are concerned about increasing patient costs, whether lower prices paid to pharmaceutical companies will reduce the choice of medicines and whether generic medicines are right for them.
Date:   Jan 2005
Title:   Submission to the Public Consultation Document: Australia - United States Free Trade Agreement (AUSFTA) Implementation of the Obligations to Improve Transparency of the Pharmaceutical Benefits Scheme (PBS)
Publisher:   Consumers' Health Forum of Australia (CHF)
Description:   Outlines the need for improved transparency and understanding of the processes for listing medicines on the Pharmaceutical Benefits Scheme (PBS), including consumer participation.
Date:   Aug 2004
Title:   Underneath the RADAR: moxifloxacin
Publisher:   Australian Prescriber
Description:   The quinolone antibiotic moxifloxacin has been listed on the Pharmaceutical Benefits Scheme (PBS), for the oral treatment of community-acquired pneumonia in adults and children over 12 years old who have immediate hypersensitivity to penicillin. This new listing extends the number of patients who can be treated with moxifloxacin.
Date:   Dec 2003
Title:   EpiPen and EpiPen Jr recommended for PBS listing
Publisher:   Australasian Society of Clinical Immunology and Allergy (ASCIA)
Description:   EpiPen and EpiPen Jr are pre-loaded syringes that inject a single dose of adrenaline for the emergency treatment of adults and children who experience severe and potentially life-threatening allergic reactions (anaphylaxis, or 'allergic shock').
Date:   Nov 2003
Title:   Your questions to the PBAC. Availability of bulking and osmotic laxative agents as pharmaceutical benefits
Publisher:   Australian Prescriber
Description:   The PBAC is reluctant to recommend laxative products for listing on the PBS and considers that other measures such as modification of diet can be used in the treatment of constipation in most patients.
Date:   Apr 2003
Results 1 to 20 displayed.
1    2